This is where users typically notice the most visible changes in body composition and energy levels
Revolutionary Incretin Mechanism GLP1-R functions as a selective agonist for GLP-1 receptors found throughout the body, particularly in pancreatic islets, brain, cardiovascular tissue, and gastrointestinal tract

Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
Insulin resistance, visceral adiposity, gut permeability, and metabolic endotoxemia create a baseline inflammatory state that lowers the threshold for autoimmune flares